Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Radius, 3M ink development agreement
July 2011
SHARING OPTIONS:

CAMBRIDGE, Mass.Radius Health Inc. and 3M Drug Delivery Systems recently signed a collaborative agreement to develop a transdermal delivery option of BA058, Radius' novel, proprietary PTHrP (parathyroid hormone-related protein) analog for treating osteoporosis. The BA058 Microneedle Patch will utilize 3M's Microstructured Transdermal System microneedle technology to administer BA058 through the skin as opposed to subcutaneous injection. Terms and financial details were not disclosed. The BA058 Microneedle Patch is undergoing Phase I clinical studies, and in recent Phase II human testing of an injectable form of BA058, the product served to significantly increase bone mineral density at both the lumbar spine and femoral neck after six months of therapy. Dr. C. Richard Lyttle, president and CEO of Radius, said in a statement that given its convenience, "the BA058 Microneedle Patch will be well-positioned to drive expansion of the osteoporosis market."


Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.